Filtered By:
Source: American Heart Journal
Condition: Hypertension
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 44 results found since Jan 2013.
Reducing cardiovascular risk through treatment of obstructive sleep apnea: 2 methodological approaches
This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovas...
Source: American Heart Journal - December 22, 2015 Category: Cardiology Source Type: research
Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)
Conclusion Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research
Rationale and Design of the Medication adherence Improvement Support App For Engagement – Blood Pressure (MedISAFE-BP) Trial
Discussion The MedISAFE-BP trial is the first study to rigorously evaluate an mhealth application's effect on blood pressure and medication adherence. The results will inform the potential effectiveness of this simple system in improving cardiovascular disease risk factors and clinical outcomes.
Source: American Heart Journal - December 9, 2016 Category: Cardiology Source Type: research
National Patterns in Intensity and Frequency of Outpatient Care for Apparent Treatment-Resistant Hypertension
In conclusion, many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.
Source: American Heart Journal - January 20, 2017 Category: Cardiology Source Type: research
Rationale and design of the Medication adherence Improvement Support App For Engagement —Blood Pressure (MedISAFE-BP) trial
Discussion The MedISAFE-BP trial is the first study to rigorously evaluate an mhealth application's effect on blood pressure and medication adherence. The results will inform the potential effectiveness of this simple system in improving cardiovascular disease risk factors and clinical outcomes.
Source: American Heart Journal - February 2, 2017 Category: Cardiology Source Type: research
Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial
Conclusion In the CHAMPION-PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical Perspectives. What's known? Cangrelor is a novel, intravenous, potent, and rapidly-acting P2Y12 inhibitor, that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of...
Source: American Heart Journal - March 9, 2017 Category: Cardiology Source Type: research
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Conclusion In the CHAMPION PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical perspectives What's known? Cangrelor is a novel, intravenous, potent, and rapidly acting P2Y12 inhibitor that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of i...
Source: American Heart Journal - April 18, 2017 Category: Cardiology Source Type: research
Contemporary rates and correlates of statin use and adherence in non-diabetic adults with cardiovascular risk factors: The KP CHAMP study
Conclusions There remain opportunities for improving prevention in patients at risk for cardiovascular events. Our study identified certain patient subgroups that may benefit from interventions to enhance medication adherence, particularly by minimizing treatment gaps and discontinuation of statin therapy within the first year of treatment.
Source: American Heart Journal - August 24, 2017 Category: Cardiology Source Type: research
Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study
Conclusions There remain opportunities for improving prevention in patients at risk for cardiovascular events. Our study identified certain patient subgroups that may benefit from interventions to enhance medication adherence, particularly by minimizing treatment gaps and discontinuation of statin therapy within the first year of treatment.
Source: American Heart Journal - September 28, 2017 Category: Cardiology Source Type: research
Variation in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the IMPACT ® Registry
Conclusion There is measurable variation in transcatheter closure of PDA and ASD. Further research is necessary to study whether this affects outcomes or resource utilization.
Source: American Heart Journal - November 3, 2017 Category: Cardiology Source Type: research
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients
Conclusion In patients with compensated HCV-related cirrhosis, Asian ethnic origin, arterial hypertension, smoking and low serum albumin are independent predictive factors of cardiovascular events, while a sustained virological response is associated with a decreased rate of cardiovascular events.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research
Lessons learned about stress and the heart after major earthquakes
Publication date: Available online 6 June 2019Source: American Heart JournalAuthor(s): Robert A. KlonerAbstractThere is evidence that certain stressors can trigger cardiovascular events. Several studies have now demonstrated an increase in major adverse cardiac events associated with natural disasters such as an earthquake. The purpose of this paper is to review the literature on earthquakes and cardiovascular events. Reports from 13 major quakes were reported. Earthquakes have been associated with a number of cardiac events including sudden cardiac death, fatal myocardial infarction (MI), myocardial infarction, stress car...
Source: American Heart Journal - June 6, 2019 Category: Cardiology Source Type: research
Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk From the LOOP study
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Transcatheter InterAtrial shunt device for the treatment of heart failure: Rationale and Design of the Pivotal Randomized Trial to REDUCE elevated left atrial pressure in patients with heart failure II (REDUCE LAP-HF II)
ConclusionsREDUCE LAP-HF II is designed to evaluate the clinical efficacy of the IASD device in patients with symptomatic HF with elevated LA pressure and LVEF≥40%.
Source: American Heart Journal - November 12, 2019 Category: Cardiology Source Type: research
